Generic EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE INN equivalents, pharmaceutical patent expiration information and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	CITANEST FORTE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	014763-008	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dentsply Pharm	CITANEST FORTE DENTAL	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	021383-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Septodont Inc	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	078959-001	Aug 30, 2011	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 15, 2026

Introduction

Epinephrine bitartrate and prilocaine hydrochloride are critical anesthetic agents with distinct clinical applications. Their market trajectories are driven by regulatory environments, patent statuses, manufacturing costs, and evolving clinical needs.

Epinephrine Bitartrate: Market Structure and Growth Drivers

Regulatory Landscape

Epinephrine is approved worldwide as a vasoconstrictor for local anesthesia and emergency treatment of anaphylaxis[1]. It is primarily marketed as a generic drug, with limited proprietary formulations due to expired patents, which constrains premium pricing.

Market Size and Revenue Estimates

The global epinephrine market was valued at approximately USD 2.2 billion in 2022. Expected compound annual growth rate (CAGR) is around 4.2% through 2028. The North American region dominates, accounting for over 45% of revenue, driven by high adoption rates in hospitals and clinics[2].

Manufacturing and Cost Considerations

Manufacturing costs are relatively low due to synthesized production. Cost efficiencies have increased with process improvements, maintaining margins despite commoditization.

Key Market Players

Major firms include Mylan, Pfizer, and Teva, primarily offering generic formulations. No new patent protections limit market entry, which sustains price competition.

Market Challenges and Opportunities

Challenges: Price erosion due to generic competition; supply chain disruptions increasing raw material costs.
Opportunities: New delivery devices (auto-injectors) and combination products with other anesthetics.

Prilocaine Hydrochloride: Market Dynamics and Financial Outlook

Regulatory and Patent Status

Prilocaine, approved for local anesthesia, faces similar patent expirations as epinephrine, with several generic manufacturers. No recent patent protections are active, exerting downward pressure on prices[3].

Market Performance and Projections

The global prilocaine market was valued at nearly USD 200 million in 2022, with an estimated CAGR of 3.8% until 2028. The Asia-Pacific region leads growth, driven by increasing dental and surgical procedures[4].

Cost Structure and Manufacturing

Prilocaine production requires specialized synthesis, but economies of scale have reduced manufacturing costs. Price competition among generics limits revenue per unit.

Key Industry Players

Companies such as Akorn and Piramal dominate, with incremental product innovation mainly in delivery systems rather than formulations.

Opportunities and Risks

Opportunities: Development of extended-release formulations; incorporation into combination anesthetic kits.
Risks: Competitive pricing pressures; regulatory scrutiny over safety profiles.

Financial Trajectory and Investment Considerations

Historical Revenue Trends

Both drugs have maintained stable revenues, with slight declines attributable to generic competition and market saturation. No significant patent-driven pricing power exists currently.

Forecasting Future Earnings

Epinephrine: Steady growth driven by increased adoption in emergency care; potential expansion into new delivery methods.
Prilocaine: Moderate growth linked to expanding dental and outpatient procedures.

Profitability Outlook

Margins remain compressed; innovation in delivery mechanisms or combination therapies could improve profitability. R&D investments are minimal due to the mature nature of these products.

Market Risks and Navigational Strategies

Pricing Pressure: Heightened competition favors price reductions. Market players must leverage supply chain efficiencies.
Regulatory Changes: Modifications in drug safety regulations could impact formulations or approvals.
Supply Chain Disruptions: Raw material availability affecting production costs.

Strategies include diversification of formulations, investment in alternative delivery systems, and geographic expansion into emerging markets.

Key Takeaways

Both epinephrine bitartrate and prilocaine hydrochloride operate within mature, highly competitive markets.
Revenue growth is driven primarily by volume expansion rather than price premiums.
Market players focus on innovation in delivery systems and product combinations to differentiate offerings.
Competition and patent expirations exert continuous downward pressure on pricing and margins.
Emerging markets present growth opportunities, particularly in Asia-Pacific regions.

FAQs

How does patent expiration affect the market for epinephrine and prilocaine?
Patent expirations allow multiple generic manufacturers to enter, increasing competition, reducing prices, and suppressing margins.
What factors could lead to increased demand for these drugs?
Rising global healthcare access, more procedural applications, and innovations in delivery systems can enhance demand.
Are there any upcoming regulatory changes that could impact these drugs?
Potential changes in safety regulations or labeling requirements could influence market dynamics but have not been announced recently.
What are the main competitive strategies in this market?
Strategies include process optimization, development of advanced delivery devices, and geographic expansion, especially into emerging markets.
What is the outlook for profitability given current market conditions?
Profitability remains challenged by intense price competition, with growth opportunities tied to product innovation and operational efficiencies.

Sources

[1] GlobalData. "Epinephrine Market Report," 2022.
[2] Fortune Business Insights. "Epinephrine Market Size, Share & Industry Analysis," 2023.
[3] U.S. Food and Drug Administration. "Drug Approvals and Patent Status," 2022.
[4] Research and Markets. "Prilocaine Market Forecast," 2023.

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	8
DailyMed Link:	epinephrine bitartrate; prilocaine hydrochloride at DailyMed

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

Epinephrine bitartrate; prilocaine hydrochloride - Generic Drug Details

What are the generic sources for epinephrine bitartrate; prilocaine hydrochloride and what is the scope of patent protection?

Summary for epinephrine bitartrate; prilocaine hydrochloride

Pharmacology for epinephrine bitartrate; prilocaine hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for epinephrine bitartrate; prilocaine hydrochloride

US Patents and Regulatory Information for epinephrine bitartrate; prilocaine hydrochloride

Market Dynamics and Financial Trajectory for Epinephrine Bitartrate and Prilocaine Hydrochloride

Make Better Decisions: Try a trial or see plans & pricing